NJ; Phillips Petroleum Company, Bartlesville, OK; and Sun Company, Inc., Linwood, PA. The nature and objective of the venture is to deliver piping inspection technology which is capable of inspecting, detecting and measuring corrosion on above ground piping and pipe supporters.

Participation in this venture will remain open to all interested persons and organizations until the final Project Completion Date which is presently anticipated to occur approximately twenty-eight (28) months after the Project commences. The participants intend to file additional written notifications disclosing all changes in its membership. Information regarding participation in the project may be obtained from Emery B. Lendvai-Lintner, Exxon Research and Engineering Company, P.O. Box 181, Florham, Park, NJ 07932–0101.

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 96–31924 Filed 12–16–96; 8:45 am]

BILLING CODE 4410–11–M

Drug Enforcement Administration

Manufacturer of Controlled Substances Notice of Registration

By Notice dated June 18, 1996, and published in the Federal Register on June 26, 1996, (61 FR 33140), Arenol Chemical Corporation, 189 Meister Avenue, Somerville, New Jersey 08876, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
2,5-Dimethoxyamphetamine (7396)	I
3,4-Methylenedioxyamphetamine (7400)	I
Difenoxin (9168)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Methylphenidate (1724)	II

No comments or objections have been received. However, by letter dated October 29, 1996, Arenol has requested that methylphenidate (1724) be deleted from its application for registration as a bulk manufacturer. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Arenol Chemical Corporation to manufacture the listed controlled substances is consistent with the public interest at this time. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted, with the exception of methylphenidate.

Dated: December 2, 1996.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 96–31888 Filed 12–16–96; 8:45 am]

BILLING CODE 4410–09–M

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated September 4, 1996, and published in the Federal Register on September 19, 1996 (61 FR 49351), Eli Lilly Industries, Inc., Chemical Plant, Kilometer 146.7, State Road 2, Mayaguez, Puerto Rico 00680, made application for renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of dextropropoxyphene, bulk (non-dosage forms) (9273) a basic class of controlled substance listed in Schedule II.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Eli Lilly Industries, Inc. to manufacture the listed controlled substance is consistent with the public interest at this time. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed above is granted.

Dated: December 2, 1996.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 96–31887 Filed 12–16–96; 8:45 am]

BILLING CODE 4410–09–M

[DEA #153F]

Controlled Substances: Established Initial 1997 Aggregate Production Quotas

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of aggregate production quotas for 1997.

SUMMARY: This notice establishes initial 1997 aggregate production quotas for controlled substances in Schedule I and II of the Controlled Substances Act (CSA).

EFFECTIVE DATE: This order is effective upon December 17, 1996.

FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug & Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537; Telephone: (202) 307–7183.

SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in Schedule I and II. This responsibility has been delegated to the Administrator of the DEA pursuant to Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations.

On October 17, 1996, a notice of the proposed initial 1997 aggregate production quotas for certain controlled substances in Schedule I and II was published in the Federal Register (61 FR 54222). All interested person were invited to comment on or before November 18, 1996. The following comments were received.

A company commented that the proposed 1997 initial aggregate production quota for fentanyl is insufficient to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the maintenance of reserve stocks. Based on current 1996 sales and inventories, and 1997 export requirements, the DEA increased the 1997 initial aggregate production quota for fentanyl.

A company commented that the proposed initial 1997 aggregate production quota for methylphenidate is insufficient to provide for the estimated medical, scientific, research and industrial needs of the United States and for the establishment of reserve stocks. After a review of current 1996 manufacturing quotas and 1997 customer requirements, the DEA has determined that no adjustment is necessary at this time.

One company commented that the proposed 1997 initial aggregate production quota for oxymorphone is insufficient to provide for the estimated medical, scientific, research and industrial needs of the United States. Based on a review of 1997 product development requirements, the DEA adjusted the initial 1997 aggregate

production quota for oxymorphone accordingly.

Another company commented that the proposed initial 1997 aggregate production quotas for alfentanil, diphenoxylate, noroxymorphone, and oxycodone (for sale) are insufficient to meet the estimated medical, scientific, research and industrial needs of the United States. After a review of 1996 manufacturing quotas, current 1996 sales and inventories, 1997 export requirements and research and product development requirements, the DEA agrees that increases are necessary for diphenoxylate, noroxymorphone and oxycodone. Regarding alfentanil, DEA determined that the proposed initial 1997 aggregate production quota is sufficient to meet 1997 requirements.

The DEA received updated information from a manufacturer regarding levo-alpha-acetylmethadol and methadone intermediate (for conversion) and from two manufacturers concerning methadone (for sale), which necessitates adjustments of the initial 1997 aggregate production quotas for these substances. The adjustments are increases which will provide for the estimated medical, scientific, research and industrial needs of the United States and for the establishment and maintenance of reserve stocks. Therefore, DEA adjusted the 1997 initial aggregate production quotas for levo-alpha-acetylmethadol, methadone (for sale) and methadone intermediate (for conversion) accordingly.

Concerning lysergic acid diethylamide and N,N-dimethylamphetamine, the DEA increased the 1997 initial aggregate production quotas for these substances since applications made by several companies for these substances were not taken into consideration in the proposal.

A company commented that the proposed initial 1997 aggregate production quota for N-ethylamphetamine is insufficient to provide for the estimated medical, scientific, research and industrial needs of the United States, and for export requirements. Since the commenter is not registered with DEA to manufacture this substance, DEA will consider this request at a later time when the proper registration is obtained.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 12612, and it has been determined that this meter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

The Deputy Administrator hereby certifies that this action will have no significant economic impact upon small entities whose interest must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601, et seq. The establishment of annual aggregate production quotas for Schedule I and II controlled substances is mandated by law and by international treaty obligations. Aggregate production quotas apply to approximately 200 DEA registered bulk and dosage from manufacturers of Schedule I and II controlled substances. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

Therefore, under the authority vested in the Attorney General by Section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator, by Section 0.104 of Title 28 of the Code of Federal Regulations, the Deputy Administrator hereby orders that the 1997 initial aggregate production quotas, expressed in grams of anhydrous acid or base, be established as follows:

2,5-Dimethoxy-4-ethylamphetamine (DOET)	2
3-Methylfentanyl	14
3-Methylthiofentanyl	2
3,4-Methylenedioxyamphetamine (MDA)	22
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)	27
3,4-Methylenedioxymethamphetamine (MDMA)	7
3,4,5-Trimethoxyamphetamine	2
4-Bromo-2,5-Dimethoxyamphetamine	2
4-Bromo-2,5-Dimethoxyphenethylamine (2–CB)	2
4-Methoxyamphetamine	17
4-Methylaminorex	2
4-Methyl-2,5-Dimethoxyamphetamine (DOM)	2
5-Methoxy-3,4-Methylenedioxyamphetamine	2
Acetyl-alpha-methylfentanyl	2
Acetylmethadol	7
Alpha-acetylmethadol	7
Alpha-ethyltryptamine	2
Alpha-methadol	2
Alpha-methylfentanyl	2
Alpha-methylthiofentanyl	2
Aminorex	7
Beta-acetylmethadol	2
Beta-hydroxyfentanyl	2
Beta-hydroxy-3-methylfentanyl	2
Beta-methadol	2
Bufotenine	2
Cathinone	9
Codeine-N-oxide	2
Difenoxin	14,000
Dihydromorphine	7
Ethylamine Analog of PCP	5
Heroin	2
Lysergic acid diethylamide (LSD)	32

Mescaline	7
Methaqualone	17
Methcathinone	11
Morphine-N-oxide	2
N-Ethylamphetamine	7
N-Hydroxy-3,4-Methylenedioxyamphetamine	2
N,N-Dimethylamphetamine	7
N,N-Dimethyltryptamine	7
Norlevorphanol	2
Normethadone	7
Normorphine	7
Para-fluorofentanyl	2
Pholcodine	2
Psilocin	2
Psilocybin	2
Tetrahydrocannibinols	25,100
Thiofentanyl	2
Thiophene Analog of Phencyclidine	5
Psilocin	2
Psilocybin	2
Tetrahydrocannibinols	25,100
Thiofentanyl	2
Thiophene Analog of Phencyclidine	5

Schedule II

1-Phenylcyclohexylamine	10
1-Piperidinocyclohexanecarbonitrile (PCC)	12
Alfentanil	9,300
Amobarbital	15
Amphetamine	2,968,000
Carfentanil	500
Cocaine	550,100
Codeine (for sale)	49,103,000
Codeine (for conversion)	19,679,000
Desoxyephedrine	1,422,000
1,361,000 grams of levodesoxyephedrine for use in a noncontrolled, nonprescription product and 61,000 grams for methamphetamine.	
Dextropropoxyphene	116,469,000
Dihydrocodeine	255,100
Diphenoxylate	1,572,000
Ecgonine (for conversion)	651,000
Ethylmorphine	12
Fentanyl	193,000
Glutethimide	2
Hydrocodone (for sale)	13,891,000
Hydrocodone (for conversion)	1,769,000
Hydromorphone	563,000
Isomethadone	12
Levo-alpha-acetylmethadol (LAAM)	356,000
Levomethorphan	2
Levorphanol	16,400
Meperidine	9,843,000
Methadone (for sale)	3,977,000
Methadone (for conversion)	364,000
Methadone Intermediate (for conversion)	5,275,000
Methamphetamine (for conversion)	723,000
Methylphenidate	13,824,000
Morphine (for sale)	11,126,000
Morphine (for conversion)	68,165,000
Noroxymorphone (for sale)	30,000
Noroxymorphone (for conversion)	2,000,000
Opium	937,000
Oxycodone (for sale)	6,634,000
Oxycodone (for conversion)	1,200
Oxymorphone	56,000

Dated: December 10, 1996.

James S. Milford,

Acting Deputy Administrator.

[FR Doc. 96–31889 Filed 12–16–96; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF LABOR

Pension and Welfare Benefits Administration

[Application No. D–10227 and 10232, et al.]

Proposed Exemptions; Real Estate Equity Trust No. 1 (the Trust)

AGENCY: Pension and Welfare Benefits Administration, Labor.

ACTION: Notice of proposed exemptions.

SUMMARY: This document contains notices of pendency before the Department of Labor (the Department) of proposed exemptions from certain of the prohibited transaction restriction of the Employee Retirement Income Security Act of 1974 (the Act) and/or the Internal Revenue Code of 1986 (the Code).

Written Comments and Hearing Requests

Unless otherwise stated in the Notice of Proposed Exemption, all interested persons are invited to submit written comments, and with respect to exemptions involving the fiduciary prohibitions of section 406(b) of the Act, requests for hearing within 45 days from the date of publication of this Federal Register Notice. Comments and request for a hearing should state: (1) The name, address, and telephone number of the person making the comment or request, and (2) the nature of the person's interest in the exemption and the manner in which the person would be adversely affected by the exemption. A request for a hearing must also state the issues to be addressed and include a general description of the evidence to be presented at the hearing. A request for a hearing must also state the issues to be addressed and include a general description of the evidence to be presented at the hearing.

ADDRESSES: All written comments and request for a hearing (at least three copies) should be sent to the Pension and Welfare Benefits Administration, Office of Exemption Determinations, Room N–5649, U.S. Department of Labor, 200 Constitution Avenue, N.W., Washington, D.C. 20210. Attention: Application No. stated in each Notice of Proposed Exemption. The applications for exemption and the comments received will be available for public inspection in the Public Documents Room of Pension and Welfare Benefits Administration, U.S. Department of Labor, Room N–5507, 200 Constitution Avenue, N.W., Washington, D.C. 20210.

Notice to Interested Persons

Notice of the proposed exemptions will be provided to all interested persons in the manner agreed upon by the applicant and the Department within 15 days of the date of publication in the Federal Register. Such notice shall include a copy of the notice of proposed exemption as published in the Federal Register and shall inform interested persons of their right to comment and to request a hearing (where appropriate).

SUPPLEMENTARY INFORMATION: The proposed exemptions were requested in applications filed pursuant to section 408(a) of the Act and/or section 4975(c)(2) of the Code, and in accordance with procedures set forth in 29 CFR Part 2570, Subpart B (55 FR 32836, 32847, August 10, 1990). Effective December 31, 1978, section 102 of Reorganization Plan No. 4 of 1978 (43 FR 47713, October 17, 1978) transferred the authority of the Secretary of the Treasury to issue exemptions of the type requested to the Secretary of Labor. Therefore, these notices of proposed exemption are issued solely by the Department.

The applications contain representations with regard to the proposed exemptions which are summarized below. Interested persons are referred to the applications on file with the Department for a complete statement of the facts and representations.

Real Estate Equity Trust No. 1 (the Trust), et al. Located in Cincinnati, OH

[Exemption Application Nos. D–10227 and D–10232]

Proposed Exemption

The Department is considering granting an exemption under the authority of section 408(a) of the Act and section 4975(c)(2) of the Code and in accordance with the procedures set forth in 29 CFR Part 2570, Subpart B (55 FR 32836, August 10, 1990). If the exemption is granted, the restrictions of sections 406(a), 406 (b)(1) and (b)(2) of the Act and the sanctions resulting from the application of section 4975 of the Code, by reason of section 4975(c)(1) (A) through (E) of the Code, shall not apply to the purchase of units in the Trust by certain multiemployer pension plans (the Plans) that will enable State Street Global Advisors, Inc. (SSGA), the independent fiduciary for the Plans investing in the Trust, to make initial and subsequent equity investments on behalf of the Trust, in the Cincinnati Development Group Limited Partnership (the Partnership), which may result in a benefit inuring to Fifth Third Bank (Fifth Third), the trustee of the Trust and a party in interest with respect to the Plans.

This proposed exemption is subject to the following conditions:

(a) Each Plan investing in the Trust has total assets that are in excess of $50 million.

(b) No Plan that purchases units in the Trust that will permit the Partnership investment has, immediately following the acquisition of such units, more than 5 percent of its assets invested therein.

(c) The decision to purchase units in the Trust that will allow SSGA to make the initial and any subsequent equity contributions to the Partnership is made by a Plan fiduciary (the Second Fiduciary) which is independent of Fifth Third and its affiliates and which is not SSGA.

(d) As independent fiduciary for the Trust, SSGA determines whether—

(1) It is in the best interests of the Trust and the Plans participating therein to make the initial and subsequent investments in the Partnership;

(2) It is appropriate for the Trust to assign, transfer, pledge or otherwise encumber its interest in the Partnership provided the Trust obtains written consent from Cincinnati Development Group, LLC (CDG);

(3) It is appropriate for the Trust to withdraw as a limited partner from the Partnership or to withdraw its capital from such Partnership provided the Trust obtains the written consent of CDG;

(4) It is appropriate for the Trust to consent to the sale by CDG of substantially all of the assets of the Partnership or the transfer by CDG of its interest in the Partnership to a third party;

(5) It is appropriate for the Trust to contribute to the Partnership the amount necessary to complete construction of the Fountain Square West Project and to require that CDG release control of the Partnership to an entity designated by the Trust, if CDG fails to provide for construction cost overruns;

(6) It is appropriate for the Trust to elect to continue the Partnership by appointing a successor general partner.

(7) An entity designated by the Trust to serve as general partner is appropriate upon the occurrence of (d)(5) or (d)(6).

(e) At the time the Partnership investment is made, the terms of the transaction are at least as favorable to each Plan participating in the Trust as